Prognostic impact of baseline tumor size (BTS) on survival outcomes in patients (pts) with untreated advanced nonsmall cell lung cancer (NSCLC), PD-L1 ≥50%, treated with pembrolizumab alone

被引：0
|
作者：
Bureau, M. [1 ]
Chatelier, T. [2 ]
Perennec, T. [1 ]
Goronflot, T. [3 ]
Greilsamer, C. [4 ]
Chene, A-L. [5 ]
Affi, R. [1 ]
Bennouna, J. [1 ]
Pons-Tostivint, E. [1 ]
机构：
[1] Univ Hosp Nantes, Dept Pneumol, Thorac Med Oncol Funct Unit, Nantes, France
[2] Clin Mutualiste Estuaire, Med Oncol, St Nazaire, France
[3] Univ Hosp Nantes, Biostat Dept, Nantes, France
[4] Hosp La Roche Sur Yon, Med Oncol, La Roche Sur Yon, France
[5] Univ Hosp Nantes, Pneumol Dept, Nantes, France
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1897
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1295P
引用
收藏
页码：S1004 / S1004
页数：1
相关论文
共 50 条
  • [41] Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in Asia
    Cheng, Ying
    Yang, James Chih-Hsin
    Okamoto, Isamu
    Zhang, Li
    Hu, Jie
    Wang, Donglin
    Hu, Chengping
    Zhou, Jianying
    Wu, Lin
    Cao, Lejie
    Liu, Jiwei
    Zhang, Helong
    Sun, Hong
    Wang, Ziping
    Gao, Hongjun
    Yan, Yan
    Xiao, Suijun
    Lin, Jianxin
    Pietanza, M. Catherine
    Kurata, Takayasu
    IMMUNOTHERAPY, 2023, 15 (13) : 1029 - 1044
  • [42] Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%
    Yamaguchi, Ou
    Kaira, Kyoichi
    Hashimoto, Kosuke
    Mouri, Atsuto
    Shiono, Ayako
    Miura, Yu
    Murayama, Yoshitake
    Kobayashi, Kunihiko
    Kagamu, Hiroshi
    Kuji, Ichiei
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [43] Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%
    Ou Yamaguchi
    Kyoichi Kaira
    Kosuke Hashimoto
    Atsuto Mouri
    Ayako Shiono
    Yu Miura
    Yoshitake Murayama
    Kunihiko Kobayashi
    Hiroshi Kagamu
    Ichiei Kuji
    Scientific Reports, 10
  • [44] Impact of PD-L1 Expression on the Overall Survival of Caucasian Patients with Advanced EGFR-Mutant NSCLC Treated with Frontline Osimertinib
    Papazyan, Thomas
    Denis, Marc G.
    Sagan, Christine
    Raimbourg, Judith
    Herbreteau, Guillaume
    Pons-Tostivint, Elvire
    TARGETED ONCOLOGY, 2024, 19 (04) : 611 - 621
  • [45] Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%
    Metro, Giulio
    Banna, Giuseppe Luigi
    Signorelli, Diego
    Gili, Alessio
    Galetta, Domenico
    Galli, Giulia
    Economopoulou, Panagiota
    Roila, Fausto
    Friedlaender, Alex
    Camerini, Andrea
    Christopoulou, Athina
    Cantale, Ornella
    De Toma, Alessandro
    Pizzutilo, Pamela
    Jimenez, Beatriz
    Collazo-Lorduy, Ana
    Calles, Antonio
    Baxevanos, Panagiotis
    Linardou, Helena
    Kosmidis, Paris
    Giannarelli, Diana
    Mountzios, Giannis
    Addeo, Alfredo
    JOURNAL OF IMMUNOTHERAPY, 2020, 43 (09) : 299 - 306
  • [46] Comment on 'Impact of performance status on non-small cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab'
    Kocak, Mehmet Zahid
    ACTA ONCOLOGICA, 2021, 60 (04) : 564 - 565
  • [47] Hyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO)
    Ferrara, R.
    Caramella, C.
    Texier, M.
    Valette, C. Audigier
    Tessonnier, L.
    Mezquita, L.
    Lahmar, J.
    Mazieres, J.
    Zalcman, G.
    Brosseau, S.
    Westeel, V.
    Le Moulec, S.
    Leroy, L.
    Duchemann, B.
    Veillon, R.
    Planchard, D.
    Boucher, M-E.
    Koscielny, S.
    Soria, J-C.
    Besse, B.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
    Reck, Martin
    Rodriguez-Abreu, Delvys
    Robinson, Andrew G.
    Hui, Rina
    Csoszi, Tibor
    Fulop, Andrea
    Gottfried, Maya
    Peled, Nir
    Tafreshi, Ali
    Cuffe, Sinead
    O'Brien, Mary
    Rao, Suman
    Hotta, Katsuyuki
    Leal, Ticiana A.
    Riess, Jonathan W.
    Jensen, Erin
    Zhao, Bin
    Pietanza, M. Catherine
    Brahmer, Julie R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (21) : 2339 - +
  • [49] The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
    Banna, G. L.
    Cortellini, A.
    Cortinovis, D. L.
    Tiseo, M.
    Aerts, J. G. J., V
    Barbieri, F.
    Giusti, R.
    Bria, E.
    Grossi, F.
    Pizzutilo, P.
    Berardi, R.
    Morabito, A.
    Genova, C.
    Mazzoni, F.
    Di Noia, V
    Signorelli, D.
    Gelibter, A.
    Macerelli, M.
    Rastelli, F.
    Chiari, R.
    Rocco, D.
    Gori, S.
    De Tursi, M.
    Di Marino, P.
    Mansueto, G.
    Zoratto, F.
    Filetti, M.
    Montrone, M.
    Citarella, F.
    Marco, R.
    Cantini, L.
    Nigro, O.
    D'Argento, E.
    Buti, S.
    Minuti, G.
    Landi, L.
    Guaitoli, G.
    Lo Russo, G.
    De Toma, A.
    Donisi, C.
    Friedlaender, A.
    De Giglio, A.
    Metro, G.
    Porzio, G.
    Ficorella, C.
    Addeo, A.
    ESMO OPEN, 2021, 6 (02)
  • [50] PD-L1 Tumor Expression and Its Effect on Overall Survival among Patients with Resected Non-Small Cell Lung Cancer (NSCLC)
    Sul, Jane
    Teo, Min Yuen
    Rafee, Shereen
    Mc Fadden, Julie
    Gately, Kathy
    Barr, Martin
    Gray, Steven
    Cuffe, Sinead
    Finn, Stephen
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S827 - S827
12345